Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mitchell Humphreys

Urology Phoenix, AZ Medical Doctor

NPI 1144208430 CMS profile 324352

5779 E Mayo Blvd, Phoenix, AZ 85054

Open in the dashboard

General payments

$357,924

161 records reported · program years 2019–2025

Research payments

$352

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$788,742 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Mitchell Humphreys of Phoenix, AZ is reported in the CMS Open Payments database as having received $357,924 across 161 general payments and $352 in research payments paid to them. Separately, studies naming them as principal investigator received $788,742 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $35,758 41
2024 General $23,945 36
2023 General $961 11
2022 General $9,391 9
2021 General $12,604 18
2020 General $39,453 12
2020 Research $352 1
2019 General $235,813 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mitchell Humphreys
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Mitchell Humphreys were reported at $35,758. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Mitchell Humphreys Urology median Middle half National median
2019 $235,813 $480 $147–$1,201 $163
2020 $39,453 $246 $87–$645 $114
2021 $12,604 $358 $111–$1,000 $132
2022 $9,391 $476 $143–$1,263 $149
2023 $961 $560 $168–$1,461 $160
2024 $23,945 $563 $170–$1,464 $164
2025 $35,758 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ethicon Inc. $262,322 33 payments
  2. Boston Scientific Corporation $56,113 79 payments
  3. Gyrus ACMI, Inc. $20,447 16 payments
  4. Lumenis, Inc $10,500 3 payments
  5. Olympus Corporation of the Americas $4,435 2 payments
  6. Medical Device Business Services, Inc. $2,011 12 payments
  7. Urogen Pharma, Inc. $500 3 payments
  8. Dornier MedTech America, Inc $491 1 payment
  9. Coloplast Corp $396 5 payments
  10. KARL STORZ Endoscopy-America $215 1 payment
  11. Other $495 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $274,134 23 payments
  2. Consulting Fee $68,803 25 payments
  3. Travel and Lodging $8,998 35 payments
  4. Food and Beverage $5,989 78 payments
Products named General payments · program years 2019–2025
  1. Olympus Laser Devices $20,462 16 payments
  2. Monarch Platform $17,600 18 payments
  3. General - Oncology $11,109 6 payments
  4. General - Kidney Stone Disease $9,503 9 payments
  5. General - BPH $8,860 4 payments
  6. SOLTIVE Urology Gynecology $4,380 1 payment
  7. Soltive Urology Gynecology $4,380 1 payment
  8. Lumenis Pulse 120H $1,500 1 payment
  9. General - Therapies $1,458 7 payments
  10. Monarch $1,003 5 payments
  11. Other $5,047 37 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Urogen Pharma, Inc. $352 1 payment

Billing to Medicare

Part B · data year 2024 · 85 billing codes

Paid by Medicare

$960,762

Of which drugs: $735,718

Medicare patients

910

Average age 75

Services billed

7,861

143 women, 767 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 43%
Cancer 36%
Ischemic heart disease 35%
Chronic kidney disease 34%
Diabetes 25%
Atrial fibrillation 21%
Depression 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Bcg live intravesical instillation, 1 mg J9030 Office 46 2,750 $5,704
Injection, gemcitabine hydrochloride, 200 mg J9201 Office 12 75 $188
Injection, ceftriaxone sodium, per 250 mg J0696 Office 14 56 $20

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JELMYTO
  • UROGEN PHARMA, INC. $331
$331 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

162 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record